Focal segmental glomerulosclerosis historical perspective

	Focal segmental glomerulosclerosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Focal segmental glomerulosclerosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X-Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Focal segmental glomerulosclerosis historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Focal segmental glomerulosclerosis historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Focal segmental glomerulosclerosis historical perspective
CDC on Focal segmental glomerulosclerosis historical perspective
Focal segmental glomerulosclerosis historical perspective in the news
Blogs on Focal segmental glomerulosclerosis historical perspective
Directions to Hospitals Treating Focal segmental glomerulosclerosis
Risk calculators and risk factors for Focal segmental glomerulosclerosis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Manpreet Kaur, MD [3] Olufunmilola Olubukola M.D.[4]

Overview

Focal segmental glomerulosclerosis (FSGS) was first discovered by a Theodor Fahr, a German pathologist, in 1925, he referred to it as "lipoid nephrosis with degeneration", showing a clear association to minimal change disease.^[1]
In 1957, FSGS was then described by Dr. Arnold Rich, a pathologist at Johns Hopkins University^[2]
In 1970, Jacob Churg and colleagues finally classified FSGS as a unique renal glomerulopathy in the " Pathology of the Nephrotic Syndrome in Children: Report for the International International Study of Kidney Disease in Children" in view of its clinical and pathological features, and its steroid-resistance in comparison to minimal change disease.^[3]

The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].

↑ Fahr, T (1925). Pathologische anatomie des morbus brightii. In: Fahr T, Gruber GB, Koch M, et al. eds. Harnorgane Männliche Geschlechtsorgane. Vienna: Springer. pp. 156–472.
↑ RICH AR (1957). "A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis". Bull Johns Hopkins Hosp. 100 (4): 173–86. PMID 13426687.
↑ Churg J, Habib R, White RH (1970). "Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children". Lancet. 760 (1): 1299–302. PMID 4193942.